Bold Therapeutics to Present at BIO-Europe
The clinical-stage biopharmaceutical company will share interim Phase 2 data on its lead candidate BOLD-100 in colorectal cancer.
Updated on Nov. 2, 2026 in Cancer
Bold Therapeutics will present at the BIO-Europe conference in Cologne, Germany, on November 9, 2026, sharing interim analysis efficacy and tolerability findings for BOLD-100. The company is developing the first-in-class ruthenium-based small molecule in a global randomized Phase 2 trial for second-line metastatic colorectal cancer.
Why it matters
The presentation provides an update on a Phase 2 trial evaluating BOLD-100 combined with FOLFOX-based standard of care against standard of care alone. Earlier Phase 2 findings in biliary tract, gastric, and colorectal cancers were positive, and the company anticipates clinical milestones as BOLD-100 moves toward registrational trials.
The trial tests BOLD-100 at 500 mg/m² and 625 mg/m² alongside FOLFOX-based standard of care against standard of care alone, with results drawn from an interim analysis. Specific efficacy and tolerability outcomes have not been released ahead of the November 9 presentation.
The players
Bold Therapeutics
Bold Therapeutics is a clinical-stage biopharmaceutical company developing novel metallotherapeutics, including the ruthenium-based candidate BOLD-100.
BIO-Europe
BIO-Europe is a major annual partnering conference for the biotechnology and pharmaceutical industries held in Europe.
The details
Bold Therapeutics, a clinical-stage biopharmaceutical company developing novel metallotherapeutics, will present at BIO-Europe in Cologne. The presentation covers interim results from a global randomized Phase 2 study of BOLD-100 in second-line metastatic colorectal cancer.
Timeline
November 9-11, 2026: BIO-Europe conference in Cologne, Germany.
November 9, 2026: Bold Therapeutics presentation from 1:15 PM to 1:30 PM in Theater A.
Health Landscape
The update extends earlier positive Phase 2 findings for BOLD-100 in biliary tract, gastric, and colorectal cancers into a new interim analysis in second-line metastatic colorectal cancer. It is a step in a clinical program the company says is moving toward registrational trials.
For people with metastatic colorectal cancer, the trial evaluates whether adding BOLD-100 to standard FOLFOX-based treatment changes outcomes compared with standard treatment alone. The results are early interim data, so no change to available treatment is established by this presentation.
The takeaway
Interim Phase 2 data for BOLD-100 will be a key indicator of whether this candidate can advance toward registrational trials in colorectal cancer. Readers should watch for the full efficacy and tolerability results once they are presented.
What happens next
Bold Therapeutics will present interim efficacy and tolerability findings for BOLD-100 at BIO-Europe on November 9, 2026.
Further reading
Explore more on Cancer research and treatment developments.
Source note: This article includes information reported by Firstwordpharma.
